F. Elahi

Fibronectin mediates APOE4-driven blood–brain barrier dysfunction in Alzheimer’s disease

Blood–brain barrier (BBB) dysfunction is an early feature of Alzheimer’s disease (AD) and is particularly pronounced in individuals carrying the APOE ε4 allele, but the mechanisms linking APOE ε4 to BBB failure remain unclear. Here we show that astrocyte-derived fibronectin (FN1) is a key mediator of apolipoprotein E4...

Rapid plaque clearance with anti-amyloid therapy for Alzheimer’s disease: in consideration of donanemab treatment duration from real-world cases

ABSTRACT To assess the possibility that individualized duration of donanemab treatment might enable early pausing of therapy, and to explore the possible utility of plasma P-tau217 as a biomarker for treatment response monitoring in real-time, two unrelated patients with early-stage Alzheimer’s disease were treated wit...

Potential contributors to variable penetrance of NOTCH3 p.Arg1231Cys Variant

Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer’s Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with few treatment options, especially for APOE4/4 homozygotes who carry high genetic risk. Valiltramiprosate/ALZ-801 is an oral small-molecule inhibitor of amyloid-beta oligomer formation in late-stage development as a disease-modifying therapy for A...

CSF fibrinogen predicts longitudinal Tau accumulation in cognitively unimpaired older adults

Fibrinogen represents a sensitive marker of BBB leakage, but whether it modifies longitudinal tau progression in cognitively unimpaired (CU) individuals remains unknown.